Connect with us

Health

FDA’s COVID-19 Vaccine Safety Claims Lack Solid Evidence—Why Overreaction Could Harm Public Health

COVID-19 vaccine safety: The FDA’s claims about COVID-19 vaccine deaths in children lack strong evidence and could restrict vaccine access. Learn why experts say VAERS reports aren’t proof, and how overreacting may harm public health and trust in vaccines.

Published

on

FDA’s COVID-19 Vaccine Safety Claims Lack Solid Evidence—Why Overreaction Could Harm Public Health
The FDA has provided no evidence that children died because of receiving a COVID-19 vaccine.
Anchiy/E+ via Getty Images

FDA claims on COVID-19 vaccine safety are unsupported by reliable data – and could severely hinder vaccine access

Frank Han, University of Illinois Chicago

The Food and Drug Administration is seeking to drastically change procedures for testing vaccine safety and approving vaccines, based on unproven claims that mRNA-based COVID-19 vaccines caused the death of at least 10 children.

The agency detailed its plans in a memo released to staff on Nov. 28, 2025, which was obtained by several news outlets and published by The Washington Post.

Citing an internal, unpublished review, the memo, written by the agency’s top vaccine regulator, Vinay Prasad, attributes the children’s deaths to myocarditis, an inflammation of the heart muscle. And it says the deaths were reported to the Vaccine Adverse Event Reporting System, or VAERS, but provides no evidence that the vaccines caused the deaths.

 

COVID-19 vaccine safety

The death of children due to an unsafe vaccine is a serious allegation. I am a pediatric cardiologist who has studied the link between COVID-19 vaccines and heart-related side effects such as myocarditis in children. To my knowledge, studies to date have shown such side effects are rare, and severe outcomes even more so. However, I am open to new evidence that could change my mind.

But without sufficient justification and solid evidence, restricting access to an approved vaccine and changing well-established procedures for testing vaccines would carry serious consequences. These moves would limit access for patients, create roadblocks for companies and worsen distrust in vaccines and public health.

In my view, it’s important for people reading about these FDA actions to understand how the evidence on a vaccine’s safety is generally assessed.

Determining cause of death

The FDA memo claims that the deaths of these children were directly related to receiving a COVID-19 immunization.

From my perspective as a clinician, it is awful that any child should die from a routine vaccination.

However, health professionals like me owe it to the public to uphold the highest possible standards in investigating why these deaths occurred. If the FDA has evidence demonstrating something that national health agencies worldwide have missed – widespread child deaths due to myocarditis caused by the COVID-19 vaccine – I don’t doubt that even the most pro-vaccine physician will listen. So far, however, no such evidence has been presented.

Advertisement
Get More From A Face Cleanser And Spa-like Massage

While a death logged in VAERS is a starting point, on its own it is insufficient to conclude whether a vaccine caused the death or other medical causes were to blame.

To demonstrate a causal link, FDA staff and physicians must align the VAERS report with physicians’ assessments of the patient, as well as data from other sources for monitoring vaccine safety. These include PRISM, which logs insurance claims data, and the Vaccine Safety Datalink, which tracks safety signals in electronic medical records.

It’s known that most deaths logged only in VAERS of children who recently received vaccines have been incorrectly attributed to the vaccines – either by accident or in some cases on purpose by anti-vaccine activists.

Heart-related side effects of COVID-19 vaccines

In his Substack and Twitter accounts, Prasad has said that he believes the rate of severe cardiac side effects after COVID-19 vaccination is severely underestimated and that the vaccines should be restricted far more than they currently are.

In a July 2025 presentation, Prasad quoted a risk of 27 cases per million of myocarditis in young men who received the COVID-19 vaccine. A 2024 review suggested that number was a bit lower – about 20 cases out of 1 million people. But that same study found that unvaccinated people had greater risk of heart problems after a COVID-19 infection than vaccinated people. In a different study, people who got myocarditis after a COVID-19 vaccination developed fewer complications than people who got myocarditis after a COVID-19 infection.

Existing vaccine safety infrastructure in the U.S. successfully identifies dangers posed by vaccines – and did so during the COVID-19 pandemic. Today, most COVID-19 vaccines in the U.S. rely on mRNA technology. But as vaccines were first emerging during the COVID-19 pandemic, two pharmaceutical companies, Janssen and AstraZeneca, rolled out a vaccine that used a different technology, called a viral vector. This type of vaccine had a very rare but genuine safety problem that was detected.

A report in VAERS is at most a first step to determining whether a vaccine caused harm.

VAERS, the Vaccine Safety Datalink, clinical investigators in the U.S. and their European counterparts detected that these vaccines did turn out to cause blood clotting. In April 2021, the FDA formally recommended pausing their use, and they were later pulled from the market.

Death due to myocarditis from COVID-19 vaccination is exceedingly rare. Demonstrating that it occurred requires proof that the person had myocarditis, evidence that no other reasonable cause of death was present, and the absence of any additional cause of myocarditis. These factors cannot be determined from VAERS data, however – and to date, the FDA has presented no other relevant data.

A problematic vision for future vaccine approvals

Currently, vaccines are tested both by seeing how well they prevent disease and by how well they generate antibodies, which are the molecules that help your body fight viruses and bacteria.

Some vaccines, such as the COVID-19 vaccine and the influenza vaccine, need to be updated based on new strains. The FDA generally approves these updates based on how well the new versions generate antibodies. Since the previous generation of vaccines was already shown to prevent infection, if the new version can generate antibodies like the previous one, researchers assume its ability to prevent infection is comparable too. Later studies can then test how well the vaccines prevent severe disease and hospitalization.

Advertisement
Get More From A Face Cleanser And Spa-like Massage

The FDA memo says this approach is insufficient and instead argues for replacing such studies with many more placebo-controlled trials – not just for COVID-19 vaccines but also for widely used influenza and pneumonia vaccines.

That may seem reasonable theoretically. In practice, however, it is not realistic.

Today’s influenza vaccines must be changed every season to reflect mutations to the virus. If the FDA were to require new placebo-controlled trials every year, the vaccine being tested would become obsolete by the time it is approved. This would be a massive waste of time and resources.

A pharmacy with a sign advertising flu shots
Influenza vaccines must be updated for every flu season.
Jacob Wackerhausen/iStock via Getty Images Plus

Also, detecting vaccine-related myocarditis at the low rate at which it occurs would have required clinical trials many times larger than the ones that were done to approve COVID-19 mRNA vaccines. This would have cost at least millions of dollars more, and the delay in rolling out vaccines would have also cost lives.

Placebo-controlled trials would require comparing people who receive the updated vaccine with people who remain unvaccinated. When an older version of the vaccine is already available, this means purposefully asking people to forgo that vaccine and risk infection for the sake of the trial, a practice that is widely considered unethical. Current scientific practice is that only a brand-new vaccine may be compared against placebo.

While suspected vaccine deaths should absolutely be investigated, stopping a vaccine for insufficient reasons can lead to a significant drop in public confidence. That’s why it’s essential to thoroughly and transparently investigate any claims that a vaccine causes harm.

Vaccine vs illness

To accurately gauge a vaccine’s risks, it is also crucial to compare its side effects with the effects of the illness it prevents.

For COVID-19, data consistently shows that the disease is clearly more dangerous. From Aug. 1, 2021, to July 31, 2022, more than 800 children in the U.S. died due to COVID-19, but very few deaths from COVID-19 vaccines in children have been been verified worldwide. What’s more, the disease causes many more heart-related side effects than the vaccine does.

Meanwhile, extensive evidence shows that COVID-19 vaccination reduces the risk of hospitalization by more than 70% and the risk of severe illness in adolescent children by 79%. Studies also show it dramatically reduces their risk of developing long COVID, a condition in which symptoms such as extreme fatigue or weakness persist more than three months after a COVID-19 infection.

Reporting only the vaccines’ risks, and not their benefits, shows just a small part of the picture.

Frank Han, Assistant Professor of Pediatric Cardiology, University of Illinois Chicago

Advertisement
Get More From A Face Cleanser And Spa-like Massage

This article is republished from The Conversation under a Creative Commons license. Read the original article.

High Demand Marks “Veggies for Veterans” Event Amid SNAP Delays

Link: https://stmdailynews.com/high-demand-marks-veggies-for-veterans-event-amid-snap-delays/

Start Your Morning Informed

Get the STM Morning Brief delivered to your inbox every weekday with breaking news, transportation updates, technology, science, and trending stories.

STM News Brief Ad 2

We don’t spam! Read our privacy policy for more info.

Continue Reading
Advertisement Sports Research

health and wellness

How Clinical Trials Really Work: Understanding the 4 Phases

Understanding how clinical trials work can help demystify the experience, while the research itself helps answer important questions about diseases, treatment options and more. If you, your healthcare team and the study researchers decide an experimental drug trial is right for you, different questions will be answered depending on which phase you participate in.

Published

on

How Clinical Trials Really Work: Understanding the 4 Phases

How Clinical Trials Really Work: Understanding the 4 Phases

(Feature Impact) The idea of participating in a clinical trial can feel overwhelming, especially if you aren’t sure what’s actually involved in the process. Understanding how clinical trials work can help demystify the experience, while the research itself helps answer important questions about diseases, treatment options and more.

According to a study by the Crohn’s & Colitis Foundation, nearly 1 in 100 Americans has inflammatory bowel disease (IBD), a term encompassing a group of conditions that includes Crohn’s disease and ulcerative colitis. These disorders affect the gastrointestinal tract and cause inflammation of the intestines, which can lead to symptoms and sometimes more complicated issues throughout the body. Research into this condition has the potential to change lives, including those of the participants themselves, yet many clinical trials face delays due to lack of enrollment.

“We need more people to get involved in clinical trials, especially those from underrepresented communities, including people of color and older adults, who have some of the highest rates of chronic disease,” said Dr. Ruby Greywoode, a gastroenterologist at Montefiore Medical Center.

Clinical trials can take many forms including medication studies, medical tests, investigating the role of diet in disease management or examining the emotional impact of living with a condition such as IBD. Each trial is typically divided into four phases, which all build on each other but are conducted separately.

If you, your healthcare team and the study researchers decide an experimental drug trial is right for you, different questions will be answered depending on which phase you participate in.

Phase 1: Is the Drug Safe to Use?

The first phase of a clinical trial is the smallest and often conducted among a group of healthy people who don’t have the condition in question. Researchers want to know how the human body reacts to the medication, determine safe dosage ranges and identify potential side effects.

Phase 2: Is the Drug Effective?

Once a drug has been evaluated for overall safety in healthy people, the clinical trial moves on to test the treatment in a slightly larger group of people. Those participating in this phase have the condition for which the new treatment is being developed. For instance, a phase 2 IBD clinical trial might give the drug to 100 people with IBD to see whether it works or causes any short-term side effects. Participants are randomly assigned to different treatment groups, which may involve different dosages or placebos (not active treatment).

18243 detail embed2Phase 3: Does It Work Better Than Currently Available Treatments?

If the second phase yields positive results, the study expands again to test the new drug against current treatment options. A phase 3 clinical trial lasts longer and involves more participants than the first two phases as researchers try to gain as much information as possible about how the drug affects different kinds of people, whether it’s better than standard treatments or placebos and what side effects may arise over a longer period of time.

At the end of this phase, the company decides whether the trial results are strong enough to submit an application to the FDA, at which point the treatment will be reviewed and potentially approved.

Phase 4: How Does the Drug Work in Real Life?

Research usually doesn’t end when a drug gets approved. Instead, it moves into the fourth phase, where companies monitor the ongoing real-world uses and effects of the medication. This can involve following thousands of patients for several years to gather as much information as possible.

If you’re one of the millions of people living with IBD in the U.S., clinical trials offer hope for a future with more treatments, less pain and healthier lives. That’s why the Crohn’s & Colitis Foundation wants to make clinical trials less mysterious, more accessible and more representative of the real people affected by these conditions.

Advertisement
Get More From A Face Cleanser And Spa-like Massage

Talk to your healthcare professional about whether a clinical trial could be right for you and explore IBD research opportunities at CrohnsColitisFoundation.org.

Clinical Trial FAQs

What is the average length of a clinical trial?

The length of clinical trials vary. They can be as short as a month or as long as one year or more. Generally, the earlier the phase, the shorter the trial period. How do you identify clinical trials you’re eligible for?

Eligibility criteria differ from study to study and may include factors like age, gender, medical history and current health status. For instance, some IBD studies may be looking for patients with mild symptoms, while others want to test treatments for moderate to severe disease. If you’re interested in a particular trial, review the criteria to see if you qualify to participate.

Is it free to participate in clinical trials?

Most clinical trials are federally or privately funded, so there is typically no cost to the participant. Associated costs like travel, time off work and childcare may or may not be covered by the trial sponsor, so it’s worth confirming these details before committing.

What if you enroll in a trial then change your mind?

You’re free to withdraw from a clinical trial at any time. If you drop out during testing, you may be asked to come in for follow-up visits to ensure your safety.

If the treatment helps, can you keep using it after the trial ends?

It depends. Some trial sponsors allow participants to continue receiving the drug voluntarily, while others only make it available after it’s been approved by the FDA.

How can you get involved in clinical trials?

Talk to your doctor about whether participating in a clinical trial may be right for you. If you’re interested in IBD clinical trials, you and your doctor can search for opportunities at crohnscolitisfoundation.org/clinical-trials-community.

“Clinical trials give patients a real way to shape the future of treatment,” Greywoode said. “It’s not just about their own care; it can help others, too. Talking openly with your doctor can help you feel more confident about getting involved.”

Photos courtesy of Shutterstock

collect?v=1&tid=UA 482330 7&cid=1955551e 1975 5e52 0cdb 8516071094cd&sc=start&t=pageview&dl=http%3A%2F%2Ftrack.familyfeatures
track

SOURCE:

Crohn’s & Colitis Foundation

Advertisement
Get More From A Face Cleanser And Spa-like Massage
https://stmdailynews.com/menopause-changes-your-mouth-most-women-have-no-idea/
Continue Reading

Health

Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it

Decades of public health campaigns have reinforced the connection between smoking and lung cancer, helping people understand that their choices can influence their health. Despite radon being the second-leading cause of lung cancer, many have never tested their home for it.

Published

on

Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it

Radon is the second leading cause of lung cancer. 8 in 10 US adults have never tested their home for it

(Sheeka Sanahori) Avoid tobacco products. Eat a healthy diet. Get recommended cancer screenings. Most U.S. adults recognize these behaviors as ways to lower their cancer risk or catch cancer early. Decades of public health campaigns have reinforced the connection between smoking and lung cancer, helping people understand that their choices can influence their health.

But U.S. adults are far less likely to recognize a risk factor they can’t control through daily habits. Radon – an odorless, invisible gas that forms naturally in the ground – is the second leading cause of lung cancer, but new research from the Prevent Cancer Foundation finds that 8 in 10 U.S. adults have never tested their home for radon. The findings are based on the Foundation’s annual Early Detection Survey of more than 7,000 U.S. adults, conducted in January 2026.

With recent high-profile lung cancer cases, such as the October diagnosis of Pope Leo XIV, who is not known to have a history of smoking cigarettes, more people are paying attention to other risk factors for lung cancer, especially for people who have never smoked.

18265 B detail embed2

Testing for radon is last on the list

When asked about preventive behaviors, 77.5% say avoiding tobacco lowers their cancer risk. Three out of four say eating a healthy diet and getting routine cancer screenings make a difference, too. More than half also named regular exercise, limiting alcohol and protecting themselves from harmful UV rays.

Testing their home for radon ranked last on the list of preventive behaviors, with only 28% listing it as a way to reduce their cancer risk.

18265 C detail embed3

Most homes go untested in every region

Radon hasn’t reached the same level of public awareness as tobacco use, diet and exercise. U.S. adults appear to overlook an environmental risk that could be inside their own homes. Eighty percent of U.S. adults report never having their homes tested for radon, and only 12% have tested within the last five years. The U.S. Environmental Protection Agency (EPA) recommends testing every two years.

In the Northeast, about 7 in 10 people (72%) have never tested their home for radon. That percentage increases for the Midwest (79%), West (82%) and South (83%). Unlike cigarettes, radon does not produce smoke and is odorless, so a test is the only way to detect its presence.

18265 D detail embed4

What it takes to find out

Radon can enter homes through the ground when uranium underneath decays. Once it’s inside, it gets trapped. People can live with high radon levels without knowing it, in older homes and new construction alike. Breaking ground on undisturbed land during construction can release more radon.

Renters can either test themselves or ask their landlord whether the home has been tested and request the results. Landlord requirements vary by state.

Test kits are inexpensive and available online and at home improvement stores. The EPA recommends taking action to reduce radon levels at 4 picocuries per liter (pCi/L) or higher, and notes that levels below that may still carry risk. If levels are high, a mitigation system can bring them down.

Beyond radon, the EPA and other health authorities cite avoiding tobacco and secondhand smoke as the most significant steps people can take to lower lung cancer risk, along with following screening guidelines based on personal risk factors.

Methodology

The Prevent Cancer Foundation commissioned Atomik Research to conduct the Foundation’s fourth annual Early Detection Survey of U.S. adults. The study consists of an online survey questionnaire, which includes several repeated measures from a previous year’s questionnaire and a primary data set gathered from a sample of 7,510 adults located throughout the United States. The sample consists of adults 21 years of age or older, and researchers implemented several demographic-based quotas in order to achieve sample characteristics similar to the overall U.S. population of adults 21 and older.

Researchers controlled for demographic variables such as biological sex, age group classification, race/ethnicity, parental status, geographic region, employment status and community classifications (e.g., urban or rural classification).

Advertisement
Get More From A Face Cleanser And Spa-like Massage

The margin of error of the overall sample is +/-1 percentage point with a confidence level of 95%. Fieldwork took place between Jan. 10 and Jan. 30, 2026. Atomik Research is an independent market research agency.

Percentages may not add up to 100% due to computer rounding, and/or the acceptance of multiple responses.

Photo courtesy of Shutterstock (family playing)

collect?v=1&tid=UA 482330 7&cid=1955551e 1975 5e52 0cdb 8516071094cd&sc=start&t=pageview&dl=http%3A%2F%2Ftrack.familyfeatures.com%2F18265%2F10675&dt=RADON IS THE SECOND LEADING CAUSE OF LUNG CANCER
track

SOURCE:

Prevent Cancer Foundation

https://stmdailynews.com/beyond-the-piggy-bank-how-to-build-your-childs-financial-future/
Continue Reading

Women's Health

Menopause changes your mouth. Most women have no idea.

Menopause changes your mouth: Many women are familiar with the most talked-about symptoms of menopause – hot flashes, disrupted sleep, brain fog and mood swings. Far fewer know that dry mouth and sensitive teeth belong on that list too.

Published

on

18132 detail intro

Menopause changes your mouth. Most women have no idea.

(Sheeka Sanahori) Many women are familiar with the most talked-about symptoms of menopause – hot flashes, disrupted sleep, brain fog and mood swings. Far fewer know that dry mouth and sensitive teeth belong on that list too.

There’s a name for it: menopause mouth. According to survey data from Delta Dental Insurance Company, 83% of women 40 and older in menopause aren’t aware of any of its symptoms.

18132 detail embed2

What menopause mouth feels like

Forty percent say they have noticed an increase in dry mouth. Another 27% have noticed more tooth sensitivity in recent months, and 26% say things taste different than they used to. You tell yourself it’s something else. You’re not drinking enough water; you’ve been brushing too hard. Menopause isn’t the first thing that comes to mind.

It adds up. Forty-five percent say oral symptoms associated with menopause, such as tooth pain, dry mouth or gum inflammation, take a toll on their confidence, mood or mental health.

18132 detail embed3

Menopause affects the whole body, mentally and physically. So why is the mouth left out?

Even after learning about this connection, 30% of women say they can’t find information about menopause-related oral health concerns. It isn’t that no one is willing to discuss it.

What makes the conversation hard to start

Three-quarters of dentists say they are comfortable discussing menopause with patients. They just want to know who they’re talking to. Most say they would want more patient history, or to know a patient was in menopause, before raising the subject. Forty-five percent say they would not bring up how menopause affects oral health unless a patient asked.

Dentists also believe that patients are already informed. Ninety-four percent say their patients are at least somewhat aware that menopause can affect oral health. So a patient says nothing about her dry mouth, because it doesn’t seem like a dental problem. The dentist doesn’t bring it up either, assuming someone already has.

18132 detail embed4

Women are asking for the information

Nearly nine in 10 women say it would help to receive specific instructions during dental visits about managing oral health during menopause. And 69% say they would be more likely to book an appointment if a primary care provider or OB-GYN had told them menopause affects oral health.

No matter who brings it up, the conversation is one worth having. Hormonal changes during menopause can increase the risk of tooth loss or tooth decay, gum disease, receding gumline or loss of jawbone density. Discussing new oral symptoms with a dentist can help women identify potential problems and address them early.

How to start the conversation with your dentist

Your dentist probably doesn’t know you’re in menopause. Start there.

Questions worth asking:

  • “Could the changes I’m noticing be related to menopause?”
  • “I haven’t had a cavity in 30 years, and now I have two. Could that be tied to hormonal changes?”
  • “What can I do about dry mouth?”
  • “Are there symptoms I should watch for?”
  • “Should I adjust my oral care routine?”

Any one of these questions can get the conversation started.

Methodology

Delta Dental Insurance Company commissioned Atomik Research to conduct two online surveys between June 25 and July 2, 2025.

The first surveyed 200 dentists throughout the United States. The margin of error is +/- 7 percentage points with a 95% confidence level.

Advertisement
Get More From A Face Cleanser And Spa-like Massage

The second surveyed 1,511 women ages 40 or older throughout the United States. To qualify, participants had to indicate they are in perimenopause, menopause or post-menopause. Those who were not sure which stage they were in, or who indicated they were not yet in one of the three stages, were excused from participation. The margin of error is +/- 3 percentage points with a 95% confidence level

Atomik Research, part of 4media group, is an independent market research agency.

Photo courtesy of Shutterstock

collect?v=1&tid=UA 482330 7&cid=1955551e 1975 5e52 0cdb 8516071094cd&sc=start&t=pageview&dl=http%3A%2F%2Ftrack.familyfeatures.com%2F18132%2F10661&dt=MENOPAUSE CHANGES YOUR MOUTH. MOST WOMEN HAVE NO IDEA
track

SOURCE:

Delta Dental Insurance Company

https://stmdailynews.com/beyond-hot-flashes-5-things-women-wish-everyone-knew-about-menopause-2/
Continue Reading

Trending